Loading stock data…
4D Molecular Therapeutics (FDMT)
$12.88+1.28 (+11.03%)
After Hours$12.87-0.01 (-0.08%)· Last close Jun 29
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
4D Molecular Therapeutics, Inc. in the Healthcare sector is trading at $12.88 with a market capitalization of $461M. Wall Street consensus targets $28.22 (9 analysts), implying a +119.1% move over the next 12 months. The stock is currently near its 52-week high of $13.33, remaining 37.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +119.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.05M↓ | $85.09M↑ | $90,000↑ | $15,000↑ | $14,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$73.62M↓ | $14.71M↑ | -$61.19M↓ | -$59.46M↓ | -$53.62M |
| Net Income | -$68.76M↓ | $19.40M↑ | -$56.88M↓ | -$54.66M↓ | -$47.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$460.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.61%
Volume
Today's trading volume
1.48M
Recent News
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
4D Molecular Therapeutics Inc (NASDAQ:FDMT) is one of the best gene therapy stocks to buy in 2026. The stock has gained nearly 30% year-to-date and surged more than 190% over the past year. Looking ahead, analysts expect FDMT stock to almost triple in the next 12 months as the company continues to advance its clinical […]
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic m
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Investors in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) had a good week, as its shares rose 7.4% to close at...
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?